Vericiguat Experience in Durable Left Ventricular Assist Device Patients

Area of Science:

• Cardiology
• Pharmacology
• Medical Devices

Background:

• Durable left ventricular assist devices (LVADs) are crucial for advanced heart failure (HF) management.
• Vericiguat, a medication targeting vascular function, may offer additional benefits to LVAD patients.

Purpose of the Study:

• To assess the safety and efficacy of Vericiguat in patients already supported by LVADs.
• To evaluate Vericiguat's impact on hemocompatibility-related adverse events (HRAE) and Vericiguat-specific adverse events.
• To determine changes in New York Heart Association (NYHA) functional class and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

Main Methods:

• Retrospective analysis of eight HeartMate3 LVAD patients treated with Vericiguat.
• Safety outcomes included HRAE and Vericiguat adverse events.
• Efficacy outcomes focused on changes in NYHA class and NT-proBNP levels.

Main Results:

• No HRAE, Vericiguat adverse events, or deaths were reported in the study cohort.
• A statistically significant increase in right ventricle stroke work index was observed (p=0.043).
• Trends toward reduced pulmonary capillary wedge pressure and increased cardiac index were noted, though not statistically significant.

Conclusions:

• Vericiguat therapy in LVAD patients demonstrates a favorable safety profile.
• Preliminary findings suggest a potential for improved efficacy, warranting further investigation.